Member Info for Timster

Would have caused her dad some serious grief no doubt!

Binned back you nasty pasty

Absolutely richob I stand corrected:

The MHRA will process the application based on the type of the trial (Type A, B or C) as described in Risk Adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products (PDF).

For certain Type A trials, the Clinical Trial Notification Scheme pages of the MHRA web site describe the process and timelines for the CTA application. Once the application is sent to the MHRA, it will be acknowledged with an accompanying note to say that the trial may go ahead after 14 days from receipt of notification if no objections have been raised. The acknowledgement letter will act as the authorisation.

For Type B and C trials, the notification scheme is not applicable and each application will be fully assessed by the MHRA. They will provide an initial response within 30 days of receipt of a valid application, with an average of 14 days for Phase 1 healthy volunteer studies.

But we are again waiting on third parties with different priorities to us.

A year ago I said we will sell everything we can make (or PL75 did but who cares). No need to thank me but I'm better than all of you!

"It is anticipated that DHSC will be procuring significant volumes over Q1 and/or Q2 2021"

fits for us....

@ndn71 for once I actually agree with you

As we know testing will be required for years. There was a good graphic on the BBC yesterday showing the countries that may vaccinate thier whole populations in 2021 then 2022 then the ones that may never get there.
The issue is mutations will be forming across the world and the original vaccines may be less effective so need to be constantly evolving along with the virus. As per the South African strain.

As I said yesterday Mologic CE marked their own test in conjunction with the Liverpool school of tropical medicine with 28 patient samples, so can't see it taking long to get Avacta's marked.
https://mologic.co.uk/mologic-receives-ce-mark-approval-for-professional-use-covid-19-rapid-antigen-test/

@sagetrade, I'm guessing the answer is here:
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.cell.com/cell/pdf/S0092-8674(20)30820-5.pdf&ved=2ahUKEwjh2bbnqdzuAhXhuXEKHWkyDVIQFjAJegQIFRAB&usg=AOvVaw2AXBqU-DfL4u4z2xszgOxn

RNS also states the development of the hybrid tests that targets S and N protein using Mologics existing technology in a single lateral flow test.

So I think it's unlikely they are now affimer based

Have you completed your homework yet leewill? I was expecting a full report of which European hospital was evaluating our test with lead names and stats ;)

Correction best test in the clinic :)

I wonder if we'll get some decent gains today as the RNS and big Al's interview sink it.

You don't go saying publicly you have the best test on the market if you don't have the best test on the market......

Ultimately who cares! This is a tinternet forum with lots of different contributors with different views, some polite, some not.
Lots of quality information posted in the time ophidian hasn't been posting, Also lots of dross. That's how all public forums work.

Shouldn't be long to wait. But surely a man of your detective prowess can discover the link avacta have to which mainland European hospital?

So 6 times better than the 300 quoted for ELISA? That sounds fantastic.

Having just relistened to the interview I'm in no doubt that this is massive and only wish I had some more cash to throw at it!

We should also have news on AVA6000 being approved for patient trials soon.

This year's inflection points are truly mind blowing.....

In summary it's taken a while as it will be (as far as Al knows) the BEST TEST IN THE WORLD MWAH HAH HAH

confirms we are top of the UK consortium to bring a high quality high volume lateral flow test to market

Giles is such a ****e interviewer :)